CFD'er er komplekse instrumenter, og der er stor risiko for at miste penge hurtigt på grund af gearing. 84% af individuelle investorer taber penge, når de handler CFD'er med denne udbyder. Du bør overveje, om du forstår, hvordan CFD'er virker, og om du har råd til at løbe en høj risiko for at miste dine penge.
US Dansk
Land • United States
    Enhed • The products and services listed on this website are not available in this location.
    English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文

    Handel Alimera Sciences, Inc. - ALIM CFD

    2.57
    1.98%
    • Opsummering
    • Historisk Data
    • Begivenheder
    • Resultatopgørelse
    • Saldo
    • Cash flow
    • Ejerskab
    Handelsbetingelser
    Spænd 0.28
    Long position, gebyr natten over

    Long position overnight fee

    Margin. Your investment $1,000.00
    Gebyr for natten over -0.025457 %
    Charges from borrowed part ($-1.02)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    Gå til platform
    		-0.025457%
    Short position, gebyr natten over

    Short position overnight fee

    Margin. Your investment $1,000.00
    Gebyr for natten over 0.003235 %
    Charges from borrowed part ($0.13)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    Gå til platform
    		0.003235%
    Gebyr natten over, tid 21:00 (UTC)
    Min. handlet mængde 1
    Valuta USD
    Margen 20%
    Aktiebørs United States of America
    Kommission på handel 0%

    *Information provided by Capital.com

    Nøglestatistikker
    Tidligere luk* 2.52
    Åben* 2.52
    1-Års Ændring* -54.84%
    Dagens Spænd* 2.5 - 2.66
    52-Ugers Spænd 1.30-7.92
    Gennemsnitlig Volumen (10 dage) 3.75M
    Gennemsnitlig Volumen (3 måneder) 12.93M
    Market Cap 19.33M
    P/E-forhold -100.00K
    Udestående aktier 7.40M
    Omsætning 55.78M
    EPS -2.44
    Dividend (Udbytte %) N/A
    Beta 1.39
    Næste indtjeningsopgørelse Jul 25, 2023

    Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Luk Change Change (%) Åben High Low
    Jun 2, 2023 2.57 0.06 2.39% 2.51 2.66 2.50
    Jun 1, 2023 2.52 -0.08 -3.08% 2.60 2.60 2.51
    May 31, 2023 2.67 0.19 7.66% 2.48 2.67 2.48
    May 30, 2023 2.52 0.05 2.02% 2.47 2.55 2.47
    May 26, 2023 2.49 0.08 3.32% 2.41 2.52 2.35
    May 25, 2023 2.48 -0.02 -0.80% 2.50 2.51 2.37
    May 24, 2023 2.41 0.23 10.55% 2.18 2.42 2.14
    May 23, 2023 2.32 -0.19 -7.57% 2.51 2.55 2.21
    May 22, 2023 2.45 0.28 12.90% 2.17 2.72 2.15
    May 19, 2023 2.23 0.12 5.69% 2.11 2.30 2.02
    May 18, 2023 2.34 -0.26 -10.00% 2.60 3.05 2.26
    May 17, 2023 1.93 0.11 6.04% 1.82 1.94 1.78
    May 16, 2023 1.79 0.21 13.29% 1.58 1.92 1.58
    May 15, 2023 1.57 -0.03 -1.88% 1.60 1.68 1.56
    May 12, 2023 1.56 -0.05 -3.11% 1.61 1.64 1.55
    May 11, 2023 1.57 0.02 1.29% 1.55 1.64 1.48
    May 10, 2023 1.52 -0.11 -6.75% 1.63 1.85 1.51
    May 9, 2023 1.63 -0.14 -7.91% 1.77 1.77 1.63
    May 8, 2023 1.73 -0.06 -3.35% 1.79 1.80 1.73
    May 5, 2023 1.83 -0.05 -2.66% 1.88 2.04 1.76

    Alimera Sciences, Inc. Events

    Tid (UTC) (UTC) Land Begivenhed
    Wednesday, July 12, 2023

    Tid (UTC) (UTC)

    13:30

    Land

    US

    Begivenhed

    Alimera Sciences Inc Annual Shareholders Meeting
    Alimera Sciences Inc Annual Shareholders Meeting

    Forecast

    -

    Previous

    -
    Tuesday, July 25, 2023

    Tid (UTC) (UTC)

    12:30

    Land

    US

    Begivenhed

    Q2 2023 Alimera Sciences Inc Earnings Release
    Q2 2023 Alimera Sciences Inc Earnings Release

    Forecast

    -

    Previous

    -
    Monday, November 13, 2023

    Tid (UTC) (UTC)

    13:30

    Land

    US

    Begivenhed

    Q3 2023 Alimera Sciences Inc Earnings Release
    Q3 2023 Alimera Sciences Inc Earnings Release

    Forecast

    -

    Previous

    -
    Se alle begivenheder
    • Årlig
    • Pr kvartal
    2022 2021 2020 2019 2018
    Total omsætning 54.129 59.029 50.82 53.943 46.599
    Omsætning 54.129 59.029 50.82 53.943 46.599
    Kost af omsætning, Total 7.977 7.03 6.941 6.626 4.308
    Bruttofortjeneste 46.152 51.999 43.879 47.317 42.291
    Totale Driftsudgifter 65.769 57.438 51.321 59.217 58.035
    Salgs/Generelle/Admin. Udgifter, Total 38.858 35.843 32.036 38.958 38.042
    Forskning & Udvikling 16.228 13.778 9.668 10.992 11.274
    Depreciation / Amortization 2.706 2.579 2.676 2.641 2.645
    Usædvanlig Udgift (Indkomst) 0 -1.792 0 1.766
    Driftsindtægter -11.64 1.591 -0.501 -5.274 -11.436
    Renteindkomst (Udgift), Netto Ikke-Drift -5.789 -4.997 -4.906 -4.953 -4.84
    Netto Indkomst Før Skat -18.079 -3.934 -5.407 -10.227 -16.276
    Netto Indkomst Efter Skat -18.107 -4.372 -5.339 -10.443 -16.382
    Netto Indkomst Før Ekstra Ting -18.107 -4.372 -5.339 -10.443 -16.382
    Netto Indkomst -18.107 -4.372 -5.339 -10.443 -16.382
    Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -18.107 -4.372 -5.339 -10.443 21.948
    Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -18.107 -4.372 -5.339 -10.443 21.948
    Fortyndet Netto Indkomst -18.107 -4.372 -5.339 -10.443 21.948
    Fortyndet Vægtet Gennemsnit Aktier 6.99685 6.59524 5.11766 4.7702 5.91587
    Fortyndet EPS Uden Ekstraordinære Ting -2.58788 -0.6629 -1.04325 -2.18921 3.71002
    Fortyndet Normaliseret EPS -2.58788 -0.83951 -1.04325 -2.18921 3.90406
    Other Operating Expenses, Total
    Totale Ekstraordinære Ting 0 0
    Total Adjustments to Net Income 0 38.33
    Andre, Netto -0.65 -0.528
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total omsætning 13.546 14.029 13.598 14.604 11.898
    Omsætning 13.546 14.029 13.598 14.604 11.898
    Kost af omsætning, Total 2.028 2.125 2.006 2.166 1.68
    Bruttofortjeneste 11.518 11.904 11.592 12.438 10.218
    Totale Driftsudgifter 16.848 16.137 17.009 16.578 16.045
    Salgs/Generelle/Admin. Udgifter, Total 9.975 9.099 9.856 9.81 10.093
    Forskning & Udvikling 4.164 4.23 4.483 3.932 3.583
    Depreciation / Amortization 0.681 0.683 0.664 0.67 0.689
    Driftsindtægter -3.302 -2.108 -3.411 -1.974 -4.147
    Renteindkomst (Udgift), Netto Ikke-Drift -1.68 -1.621 -1.567 -1.345 -1.256
    Netto Indkomst Før Skat -4.968 -3.781 -5.245 -3.098 -5.955
    Netto Indkomst Efter Skat -4.968 -3.78 -5.257 -3.115 -5.955
    Netto Indkomst Før Ekstra Ting -4.968 -3.78 -5.257 -3.115 -5.955
    Netto Indkomst -4.968 -3.78 -5.257 -3.115 -5.955
    Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -4.982 -3.78 -5.257 -3.115 -5.955
    Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -4.982 -3.78 -5.257 -3.115 -5.955
    Fortyndet Netto Indkomst -4.982 -3.78 -5.257 -3.115 -5.955
    Fortyndet Vægtet Gennemsnit Aktier 7.03223 7.00032 6.99658 6.99971 6.99074
    Fortyndet EPS Uden Ekstraordinære Ting -0.70845 -0.53998 -0.75137 -0.44502 -0.85184
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Fortyndet Normaliseret EPS -0.70845 -0.53998 -0.75137 -0.44502 -0.85184
    Usædvanlig Udgift (Indkomst) 0 0 0
    Andre, Netto 0.014 -0.052 -0.267 0.221 -0.552
    Total Adjustments to Net Income -0.014
    • Årlig
    • Pr kvartal
    2022 2021 2020 2019 2018
    Totale Nuværende Aktiver 29.413 42.16 34.906 32.745 34.848
    Likvider og Kortsigtede Investeringer 5.274 16.51 11.208 9.426 13.043
    Likvider & Lignende 5.274 16.51 11.208 9.426 13.043
    Totale Tilgodehavender, Netto 19.612 19.128 17.2 19.331 17.259
    Accounts Receivable - Trade, Net 19.612 19.128 17.2 19.331 17.259
    Total Inventory 1.605 2.679 2.746 1.39 2.405
    Prepaid Expenses 2.892 3.809 3.718 2.565 2.109
    Other Current Assets, Total 0.03 0.034 0.034 0.033 0.032
    Total Assets 42.602 58.52 50.855 50.309 54.108
    Property/Plant/Equipment, Total - Net 3.92 4.493 2.358 2.047 1.355
    Property/Plant/Equipment, Total - Gross 7.981 7.923 6.305 5.858 4.967
    Accumulated Depreciation, Total -4.061 -3.43 -3.947 -3.881 -3.612
    Intangibles, Net 8.957 10.897 12.838 14.783 16.723
    Other Long Term Assets, Total 0.129 0.137 0.753 0.734 1.182
    Total Current Liabilities 39.732 12.592 12.348 12.048 10.234
    Accounts Payable 10.088 8.706 7.461 7.077 6.355
    Accrued Expenses 3.998 3.617 3.197 4.716 3.643
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 25.646 0.269 1.69 0.255 0.236
    Other Current Liabilities, Total
    Total Liabilities 63.41 61.125 58.833 54.754 51.386
    Total Long Term Debt 18.683 43.08 42.922 38.752 38.178
    Long Term Debt 18.683 43.08 42.408 38.658 37.873
    Capital Lease Obligations 0.514 0.094 0.305
    Other Liabilities, Total 4.995 5.453 3.563 3.954 2.974
    Total Equity -20.808 -2.605 -7.978 -4.445 2.722
    Preferred Stock - Non Redeemable, Net 19.227 19.227 19.227 30.344 30.344
    Common Stock 0.07 0.069 0.057 0.05 0.701
    Additional Paid-In Capital 378.238 377.229 365.83 350.117 346.108
    Retained Earnings (Accumulated Deficit) -415.388 -397.281 -392.539 -383.863 -373.42
    Other Equity, Total -2.955 -1.849 -0.553 -1.093 -1.011
    Total Liabilities & Shareholders’ Equity 42.602 58.52 50.855 50.309 54.108
    Total Common Shares Outstanding 6.99551 6.93515 5.71937 4.96595 4.67193
    Total Preferred Shares Outstanding 0.6 0.6 0.6 0.61015 0.61015
    Long Term Investments 0.183 0.833
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Totale Nuværende Aktiver 35.675 29.413 29.76 33.073 34.753
    Likvider og Kortsigtede Investeringer 13.086 5.274 5.514 7.859 9.946
    Likvider & Lignende 13.086 5.274 5.514 7.859 9.946
    Totale Tilgodehavender, Netto 18.433 19.612 19.142 20.319 18.776
    Accounts Receivable - Trade, Net 18.433 19.612 19.142 20.319 18.776
    Total Inventory 1.215 1.605 1.786 1.656 2.452
    Prepaid Expenses 2.91 2.892 3.29 3.208 3.546
    Other Current Assets, Total 0.031 0.03 0.028 0.031 0.033
    Total Assets 48.239 42.602 43.429 47.574 49.931
    Property/Plant/Equipment, Total - Net 3.757 3.92 3.87 3.938 4.343
    Intangibles, Net 8.479 8.957 9.446 9.935 10.419
    Other Long Term Assets, Total 0.131 0.129 0.118 0.126 0.134
    Total Current Liabilities 14.173 39.732 34.01 25.431 17.006
    Accounts Payable 9.669 10.088 8.706 7.614 6.604
    Accrued Expenses 4.241 3.998 3.661 3.316 3.046
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0.263 25.646 21.643 14.501 7.356
    Total Liabilities 67.155 63.41 61.507 59.909 58.534
    Total Long Term Debt 44.312 18.683 22.492 29.297 36.245
    Long Term Debt 44.152 18.683 22.492 29.297 36.245
    Capital Lease Obligations 0.16
    Other Liabilities, Total 8.67 4.995 5.005 5.181 5.283
    Total Equity -18.916 -20.808 -18.078 -12.335 -8.603
    Preferred Stock - Non Redeemable, Net 7.728 19.227 19.227 19.227 19.227
    Common Stock 0.074 0.07 0.07 0.07 0.07
    Additional Paid-In Capital 378.146 378.238 378.005 377.847 377.541
    Retained Earnings (Accumulated Deficit) -402.081 -415.388 -411.608 -406.351 -403.236
    Other Equity, Total -2.783 -2.955 -3.772 -3.128 -2.205
    Total Liabilities & Shareholders’ Equity 48.239 42.602 43.429 47.574 49.931
    Total Common Shares Outstanding 7.39159 6.99551 6.99802 6.99546 6.99265
    Total Preferred Shares Outstanding 0.012 0.6 0.6 0.6 0.6
    Long Term Investments 0.197 0.183 0.235 0.502 0.282
    Other Current Liabilities, Total
    • Årlig
    • Pr kvartal
    2022 2021 2020 2019 2018
    Netto indkomst/Startlinje -18.107 -4.372 -5.339 -10.443 -16.382
    Likvider Fra Driftsaktiviteter -9.975 -3.224 -2.193 -4.152 -11.553
    Likvider Fra Driftsaktiviteter 2.706 2.579 2.676 2.641 2.645
    Deferred Taxes 0.116 0.61 0.031 0.454 -0.653
    Ikke-Likvide Ting 2.621 -0.692 1.829 3.377 7.084
    Cash Taxes Paid 0.232 0.112 0.11 0.239 0.239
    Likvid Rente Betalt 4.489 4.302 4.556 4.419 3.571
    Ændringer i Driftskapital 2.689 -1.349 -1.39 -0.181 -4.247
    Likvider fra Investeringsaktiviteter -0.255 -0.621 -0.62 -0.174 -0.175
    Kapitaludgifter -0.255 -0.621 -0.62 -0.174 -0.175
    Likvider fra Financieringsaktiviteter -0.302 9.823 3.882 0.869 0.95
    Financiering af Cash-Flow-Ting -0.113 0 -0.019 -2.227 -3.808
    Udstedelse (Pensionering) af Aktier, Netto 0.1 10.044 0.049 0.902 0.085
    Udstedelse (Pensionering) af Gæld, Netto -0.289 -0.221 3.852 2.194 4.673
    Udenlandsk Børs Effekter -0.708 -0.676 0.714 -0.159 -0.248
    Netto Ændring i Likviditet -11.24 5.302 1.783 -3.616 -11.026
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -4.968 -18.107 -14.327 -9.07 -5.955
    Cash From Operating Activities -2.209 -9.975 -9.724 -7.811 -6.213
    Cash From Operating Activities 0.681 2.706 2.023 1.359 0.689
    Non-Cash Items 0.507 2.621 2.095 1.318 1.027
    Cash Taxes Paid 0 0.232 0.224 0.182 0.018
    Cash Interest Paid 1.354 4.489 3.253 2.145 1.061
    Changes in Working Capital 1.571 2.689 0.485 -1.418 -1.974
    Cash From Investing Activities -0.009 -0.255 -0.171 -0.041 -0.149
    Capital Expenditures -0.009 -0.255 -0.171 -0.041 -0.149
    Cash From Financing Activities 9.998 -0.302 -0.109 -0.164 -0.062
    Financing Cash Flow Items -3.123 -0.113
    Issuance (Retirement) of Debt, Net 2.373 -0.289 -0.164 -0.204 -0.062
    Foreign Exchange Effects 0.033 -0.708 -0.998 -0.638 -0.141
    Net Change in Cash 7.813 -11.24 -11.002 -8.654 -6.565
    Issuance (Retirement) of Stock, Net 10.748 0.1 0.055 0.04
    Deferred Taxes 0.116
    Investornavn Investortype Procent udestående Aktiebeholdning Aktieændring Beholdningsdato IOmsætningsscore
    Velan Capital Investment Management LP Investment Advisor/Hedge Fund 22.4131 1659654 1401901 2023-05-17 MED
    Ocumension Therapeutics Corporation 15.4621 1144945 0 2023-04-24 LOW
    Morgan Stanley & Co. LLC Research Firm 8.9243 660832 0 2023-03-31 MED
    Caligan Partners, LP Hedge Fund 6.4657 478777 0 2023-05-17 MED
    Eiswirth (Richard S Jr) Individual Investor 4.3555 322518 500 2023-04-24 LOW
    HOOPP Investment Management Pension Fund 3.3762 250000 0 2023-03-31 HIGH
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.0071 148624 0 2023-03-31 LOW
    Ashman Philip Individual Investor 1.8004 133315 0 2023-04-24 MED
    Holland (David R) Individual Investor 1.4704 108880 500 2023-04-24 LOW
    Renaissance Technologies LLC Hedge Fund 1.3693 101394 -1100 2023-03-31 HIGH
    Skibsted (Russell L) Individual Investor 1.0196 75500 58000 2023-03-26 HIGH
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.5167 38262 0 2023-03-31 LOW
    Jones (John Philip) Individual Investor 0.4347 32186 372 2022-10-31
    Millennium Management LLC Hedge Fund 0.3884 28762 16799 2023-03-31 HIGH
    Acadian Asset Management LLC Investment Advisor/Hedge Fund 0.2639 19542 0 2023-03-31 MED
    Bridgeway Capital Management, LLC Investment Advisor 0.2471 18300 0 2023-03-31 LOW
    Perritt Capital Management, Inc. Investment Advisor 0.2431 18000 0 2023-03-31 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 0.175 12962 438 2023-03-31 LOW
    J.P. Morgan Securities LLC Research Firm 0.14 10364 9838 2023-03-31 MED
    Snisarenko (John) Individual Investor 0.135 10000 0 2023-04-24 LOW

    Hvorfor vælge Capital.com? Vores tal taler for sig selv.

    Capital.com Group

    535K+

    Handlende

    87K+

    Månedlkige, aktive klienter

    $113M+

    Månedlig investeringsvolumen

    $64M+

    Hævet hver måned

    Handelslommeregner

    Udregn dit hypotetiske P&L hvis du havde åbnet en CFD-handel på en given dato (vælg en dato) og lukket den på en anden dato (vælg en dato).

    Handelskurtage
    0
    • 1:1
    Gearing
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investering
    Handelsstørrelse (Gearing x Investering):
    Åben

    Luk

    Short Long
    Tidligere resultater er ikke en pålidelig indikator for fremtidige resultater
    Fortjeneste/Tab

    Alimera Sciences, Inc. Company profile

    Om Alimera Sciences, Inc.

    Alimera Sciences, Inc. er en lægemiddelvirksomhed. Virksomheden beskæftiger sig med markedsføring og udvikling af receptpligtige oftalmiske lægemidler. Selskabet fokuserer på sygdomme, der påvirker bagsiden af øjet eller nethinden. Selskabets kommercielle produkt, ILUVIEN, er et intravitrealt implantat, som behandler patienter ved at afgive en kontinuerlig mikrodosis af det ikke-proprietære kortikosteroid fluocinolonacetonid (FAc) i øjet i op til 36 måneder. Virksomheden er engageret i udvikling til behandling af diabetisk makulaødem (DME). DME er en sygdom i nethinden, der rammer personer med diabetes og kan føre til alvorligt synstab og blindhed. ILUVIEN kan også bruges til at forebygge tilbagefald ved tilbagevendende ikke-infektiøs uveitis, der påvirker det bageste segment af øjet (NIU-PS). Virksomheden markedsfører ILUVIEN direkte i USA, Tyskland, Det Forenede Kongerige, Portugal og Irland.

    Industry: Biopharmaceuticals

    Ste 290
    6120 Windward Parkway
    ALPHARETTA
    GEORGIA 30005
    US

    Resultatopgørelse

    • Annual
    • Quarterly

    Folk ser også

    Gold

    1,948.36 Price
    -1.480% 1D Chg, %
    Long position, gebyr natten over -0.0185%
    Short position, gebyr natten over 0.0103%
    Gebyr natten over, tid 21:00 (UTC)
    Spænd 0.30

    XRP/USD

    0.52 Price
    -1.380% 1D Chg, %
    Long position, gebyr natten over -0.0753%
    Short position, gebyr natten over 0.0069%
    Gebyr natten over, tid 21:00 (UTC)
    Spænd 0.00394

    US100

    14,557.80 Price
    +0.640% 1D Chg, %
    Long position, gebyr natten over -0.0255%
    Short position, gebyr natten over 0.0032%
    Gebyr natten over, tid 21:00 (UTC)
    Spænd 3.0

    BTC/USD

    27,068.35 Price
    -0.530% 1D Chg, %
    Long position, gebyr natten over -0.0616%
    Short position, gebyr natten over 0.0137%
    Gebyr natten over, tid 21:00 (UTC)
    Spænd 60.00

    Leder du stadig efter en mægler, du kan stole på?

    Deltag sammen med 535.000+ handlende over hele verden, der valgte at handle hos Capital.com

    1. Opret og bekræft din konto 2. Lav en inddbetaling 3. Find din handel